Researchers at the Princess Margaret Cancer Centre in Toronto have launched a large-scale study to determine if liquid biopsies can detect cancer recurrence [1].

This research matters because identifying tiny traces of tumors after initial treatment could allow doctors to intervene earlier and personalize follow-up care. If successful, the technology could reduce the uncertainty patients face during the recovery period by providing a biological marker for relapse [3].

The project, which was announced in June 2026 [1], focuses on the detection of minimal residual disease. This refers to the small number of cancer cells that remain in the body after treatment, which are often too few to be seen on traditional imaging scans [3]. By analyzing blood samples, the team aims to find these traces and forecast whether a patient will require further medical intervention [2].

Based in Ontario, the Canadian team is utilizing liquid-biopsy technology to bridge the gap between surgical removal of tumors and the eventual reappearance of clinical symptoms [4]. The multi-year effort seeks to establish whether these blood tests are reliable enough to guide critical treatment decisions in a clinical setting [1].

Traditional monitoring often relies on periodic scans and physical exams, which may only detect a recurrence once a tumor has grown to a certain size. The liquid-biopsy approach instead looks for circulating tumor DNA, or other biomarkers, in the bloodstream [3]. This method provides a less invasive way to monitor patients compared to traditional tissue biopsies [2].

The researchers are evaluating the sensitivity and specificity of these tests across a broad patient cohort to ensure the results are consistent and accurate [1]. The goal is to determine if the presence of these markers consistently predicts a relapse before it becomes visible on a scan [3].

“Liquid biopsies could detect tiny traces of tumors left after cancer treatment.”

The shift toward liquid biopsies represents a move toward 'molecular monitoring' in oncology. If these tests can reliably detect minimal residual disease, the medical community may move away from a one-size-fits-all follow-up schedule toward a precision-medicine model, where additional chemotherapy or targeted therapy is administered only to those whose blood tests indicate a high risk of relapse.